New triple therapy takes on stubborn lung cancer in early trial
NCT ID NCT07113691
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new oral drug called iadademstat combined with radiation therapy and the immunotherapy atezolizumab in people with extensive-stage small-cell lung cancer that has persisted, returned, or worsened after first-line treatment. The study will enroll about 15 participants and primarily aims to check the safety and side effects of this combination. It is not yet known whether this approach will help control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iadademstat (oral drug) combined with atezolizumab (immunotherapy) and stereotactic body radiation therapy (SBRT)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced small-cell lung cancer whose disease has not responded to or returned after initial therapy.
- What could go wrong
- This is a very early (Phase 1) and small (15 participants) trial focused on safety, not yet on effectiveness. The combination may cause significant side effects and may not shrink tumors or improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill help keep advanced lung cancer at bay?
- Cholesterol-Lowering drug may boost lung cancer immunotherapy
- Engineered immune cells take on tough lung cancer
- New hope for advanced lung cancer: chemo-radiation combo enters trial
- New drug duo aims to shrink tough lung cancer in 33-patient trial
- New hope for aggressive lung cancer: experimental drug combo enters final testing